Karyopharm Historical Financial Ratios
| KPTI Stock | USD 0.70 0.10 16.67% |
Karyopharm Therapeutics is lately reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Invested Capital of 0.0 will help investors to properly organize and evaluate Karyopharm Therapeutics financial condition quickly.
Karyopharm |
About Karyopharm Financial Ratios Analysis
Karyopharm TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Karyopharm Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Karyopharm financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Karyopharm Therapeutics history.
Karyopharm Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Karyopharm Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Karyopharm Therapeutics sales, a figure that is much harder to manipulate than other Karyopharm Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from Karyopharm Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.As of now, Karyopharm Therapeutics' ROE is increasing as compared to previous years. The Karyopharm Therapeutics' current Receivables Turnover is estimated to increase to 6.96, while Price To Sales Ratio is projected to decrease to 0.64.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 2.12 | 1.88 | 1.58 | 1.5 | Days Of Inventory On Hand | 440.53 | 295.75 | 224.75 | 219.24 |
Karyopharm Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Karyopharm Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Karyopharm Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 29.04 | 10.32 | 2.31 | 1.77 | 0.68 | 0.64 | |
| Ptb Ratio | 23.86 | 22.06 | (6.07) | (16.71) | (0.73) | (0.69) | |
| Book Value Per Share | 0.8 | 0.7 | (1.06) | (0.2) | (1.19) | (1.13) | |
| Free Cash Flow Yield | (0.16) | (0.14) | (0.23) | (0.54) | (0.94) | (0.89) | |
| Operating Cash Flow Per Share | (3.08) | (2.22) | (1.42) | (1.83) | (0.81) | (0.85) | |
| Stock Based Compensation To Revenue | 12.71 | 0.57 | 0.37 | 0.23 | 0.14 | 0.15 | |
| Capex To Depreciation | 3.21 | 0.21 | 0.15 | 7.24 | 0.19 | 0.22 | |
| Pb Ratio | 23.86 | 22.06 | (6.07) | (16.71) | (0.73) | (0.69) | |
| Ev To Sales | 28.58 | 10.61 | 2.2 | 2.01 | 1.53 | 1.45 | |
| Free Cash Flow Per Share | (3.08) | (2.23) | (1.5) | (1.83) | (0.81) | (0.85) | |
| Net Income Per Share | (3.22) | (2.72) | (1.65) | (2.02) | (1.25) | (1.32) | |
| Payables Turnover | 2.44 | 0.61 | 2.12 | 1.88 | 1.58 | 1.5 | |
| Research And Ddevelopement To Revenue | 5.32 | 2.99 | 1.4 | 0.77 | 0.95 | 0.9 | |
| Capex To Revenue | 0.005038 | 0.001342 | 0.0272 | 7.51E-4 | 8.64E-4 | 8.21E-4 | |
| Cash Per Share | 4.23 | 3.46 | 3.04 | 3.4 | 1.68 | 1.59 | |
| Pocfratio | (6.22) | (6.96) | (4.52) | (1.86) | (1.07) | (1.12) | |
| Interest Coverage | (12.1) | (6.33) | (3.77) | (5.69) | (5.44) | (5.71) | |
| Capex To Operating Cash Flow | (0.00108) | (9.05E-4) | (0.0533) | (7.89E-4) | (7.1E-4) | (7.46E-4) | |
| Pfcf Ratio | (6.22) | (6.95) | (4.29) | (1.86) | (1.07) | (1.12) | |
| Days Payables Outstanding | 149.37 | 600.46 | 171.99 | 194.16 | 230.65 | 242.19 | |
| Roe | (4.01) | (3.88) | 1.56 | 9.92 | 1.05 | 1.1 | |
| Ev To Operating Cash Flow | (6.12) | (7.16) | (4.32) | (2.11) | (2.41) | (2.53) | |
| Pe Ratio | (5.95) | (5.68) | (3.9) | (1.68) | (0.69) | (0.72) | |
| Return On Tangible Assets | (0.68) | (0.63) | (0.41) | (0.46) | (0.6) | (0.62) | |
| Ev To Free Cash Flow | (6.12) | (7.15) | (4.1) | (2.11) | (2.41) | (2.53) | |
| Earnings Yield | (0.17) | (0.18) | (0.26) | (0.59) | (1.45) | (1.38) | |
| Net Debt To E B I T D A | 0.1 | (0.19) | 0.22 | (0.27) | (1.05) | (1.0) | |
| Current Ratio | 5.9 | 974.88 | 3.5 | 4.96 | 3.37 | 3.2 | |
| Tangible Book Value Per Share | 0.8 | 0.7 | (1.06) | (0.2) | (1.19) | (1.13) | |
| Graham Number | 7.63 | 6.56 | 6.27 | 3.04 | 5.8 | 5.51 | |
| Shareholders Equity Per Share | 0.8 | 0.7 | (1.06) | (0.2) | (1.19) | (1.13) | |
| Debt To Equity | 2.24 | 2.37 | (2.15) | (10.39) | (1.28) | (1.34) | |
| Capex Per Share | 0.003325 | 0.002013 | 0.0759 | 0.001441 | 0.001657 | 0.001575 |
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.